Showing results (201-210 of 351) with videos related to
Sort By:
Pageof 36
Antiviral Therapy|May 11, 2011
Predicting antiretroviral drug resistance from the latest or the cumulative genotypeFederico Garcia, Marta Alvarez, Zoe Fox, et al.Plos One|October 8, 2014
Cost-effectiveness of HIV drug resistance testing to inform switching to second line antiretroviral therapy in low income settingsAndrew Phillips, Valentina Cambiano, Fumiyo Nakagawa, et al.AIDS (London, England)|February 8, 2011
The impact of HIV drug resistance testing on changes to treatmentLoveleen Bansi, Colette Smith, Andrew Phillips, et al.AIDS (London, England)|February 23, 2007
Is the increased risk of liver enzyme elevation in patients co-infected with HIV and hepatitis virus greater in those taking antiretroviral therapy?Paola Cicconi, Alessandro Cozzi-Lepri, Andrew Phillips, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|November 17, 2010
Impact of transmitted drug-resistance on treatment selection and outcome of first-line Highly Active Antiretroviral Therapy (HAART)Loveleen Bansi, Anna Maria Geretti, David Dunn, et al.AIDS (London, England)|January 26, 2017
Improved kidney function in patients who switch their protease inhibitor from atazanavir or lopinavir to darunavirSophie Jose, Mark Nelson, Andrew Phillips, et al.The Lancet. HIV|October 2, 2015
Health-related quality-of-life of people with HIV in the era of combination antiretroviral treatment: a cross-sectional comparison with the general populationAlec Miners, Andrew Phillips, Noemi Kreif, et al.AIDS (London, England)|October 30, 2009
Development of a didanosine genotypic resistance interpretation system based on large derivation and validation datasetsLambert Assoumou, Alessandro Cozzi-Lepri, Françoise Brun-Vézinet, et al.Plos One|January 28, 2017
Plasma HIV-1 Tropism and the Risk of Short-Term Clinical Progression to AIDS or DeathMaria Casadellà, Alessandro Cozzi-Lepri, Andrew Phillips, et al.Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 17, 2011
Time from human immunodeficiency virus seroconversion to reaching CD4+ cell count thresholds <200, <350, and <500 Cells/mm³: assessment of need following changes in treatment guidelinesSara Lodi, Andrew Phillips, Giota Touloumi, et al.Pageof 36